Nightingale Health Oyj

Equities

HEALTH

FI4000490875

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Helsinki Other stock markets 11:29:43 2024-04-26 am EDT			5-day change	1st Jan Change
1.86 ^EUR	-4.37%		+18.47%	+66.67%

Apr. 16	Finland’s Nightingale Health Plots US Expansion	MT
Apr. 16	Nightingale Health to Establish A Laboratory in the United States	CI

Nightingale Health Oyj agreed to acquire Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited.

March 06, 2024

Nightingale Health Oyj (HLSE:HEALTH) agreed to acquire Welltus Inc from Mitsui & Co., Ltd. (TSE:8031) and Kirin Holdings Company, Limited (TSE:2503) on March 7, 2024. The transaction is subject to customary terms, is expected to close on 29 March 2024.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
MITSUI & CO., LTD.	7,519 JPY	+1.86%	+5.53%	71.52B
KIRIN HOLDINGS COMPANY, LIMITED	2,273 JPY	+0.04%	+2.60%	11.69B
NIGHTINGALE HEALTH OYJ	1.86 EUR	-4.37%	+18.47%	120M

Latest news about Nightingale Health Oyj

Finland’s Nightingale Health Plots US Expansion	Apr. 16	MT
Nightingale Health to Establish A Laboratory in the United States	Apr. 16	CI
Nightingale Health and the Englander Institute for Precision Medicine At Weill Cornell Medicine Sign A Letter of Intent in Which the Parties Agree to Collaborate on the Adoption of Nightingale Health's Proprietary Technology in Healthcare and Medical Research in the United States	Apr. 16	CI
Nightingale Health Secures Blood Analysis Contract with Kaiser Foundation	Apr. 12	MT
Nightingale Health Enters into Agreement to Analyze 50,000 Blood Samples with Kaiser Foundation Health Plan, Inc	Apr. 12	CI
Nightingale Health Closes Purchase of Japan's Welltus	Mar. 29	MT
Nightingale Health Oyj completed the acquisition of Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited.	Mar. 28	CI
Nightingale Health plc Enters into an Agreement in Which It Will Analyze Blood Samples from Uganda's General Population Cohort	Mar. 19	CI
Finland-based Nightingale Health to Buy Japan's Welltus	Mar. 07	MT
Transcript : Nightingale Health Oyj, H1 2024 Earnings Call, Mar 07, 2024	Mar. 07
Nightingale Health Oyj Reports Earnings Results for the Half Year Ended December 30, 2023	Mar. 07	CI
Nightingale Health Oyj agreed to acquire Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited.	Mar. 06	CI
Singaporean Regulator Approves Nightingale Health's Blood Analysis Technology	Feb. 23	MT
Nightingale Health Oyj Receives Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore	Feb. 23	CI
Nightingale Health Lands Five New Health Risk Detection Patents in Finland	Jan. 31	MT
Nightingale Health plc Receives Five New Patents for Its Proprietary Health Risk Detection Capability	Jan. 31	CI
Suomen Terveystalo Begins Using Nightingale Health's Blood Analysis Technology in Regular Health Checks in Occupational Health	Jan. 02	CI
Terveystalo Integrates Nightingale Health's Blood Analysis Technology in Occupational Health	Jan. 02	MT
Nightingale Health Completes the Analysis of All 500,000 UK Biobank Samples Creating the Largest Blood Biomarker Database for Chronic Disease Research and Prevention	Dec. 13	CI
Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer	Nov. 27	CI
Nightingale Health and Innoquest Diagnostics Enter into Collaboration Agreement to Make Nightingale Health's Technology Accessible in the Southeast Asia Region	Nov. 15	CI
Transcript : Nightingale Health Oyj, 2023 Earnings Call, Sep 28, 2023	23-09-28
Nightingale Health Oyj Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Nightingale Health Secures Three New Patents in Finland	23-09-26	MT
Nightingale Health Receives Three New Patents Further Strengthening Its IP Portfolio	23-09-26	CI

Chart Nightingale Health Oyj

Duration

Period

More charts

Company Profile

Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Companyâs subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Ratings for Nightingale Health Oyj

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.86 EUR

Average target price

1.25 EUR

Spread / Average Target

-32.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
NIGHTINGALE HEALTH OYJ	+66.67%	120M
VEEVA SYSTEMS INC.	+4.36%	32.47B
PRO MEDICUS LIMITED	+14.14%	7.45B
SECTRA AB	+22.93%	3.89B
EVOLENT HEALTH, INC.	-16.29%	3.15B
OMNICELL, INC.	-25.96%	1.28B
LUNIT INC.	-36.14%	1.09B
SIMULATIONS PLUS, INC.	-0.13%	893M
B-SOFT CO.,LTD.	-35.42%	902M
VERADIGM INC.	-24.12%	857M

Medical Software & Technology Services